HR Opportunity : 🔎 We are looking for an Intern analyst to join our early-stage therapeutics investment team in Paris !

You are passionate and proactive to join our Paris based Biotech team ?
You'll have an exceptional opportunity to make a meaningful impact on our investments by identifying promising opportunities, conducting thorough evaluations, and contributing to deal execution and post-investment follow-up.

🗓 When? May 2025
📍 Where? Paris
📜 Contract : Internship

📌 If you want to apply and join our team please send your resume along with a paragraph about yourself to candidature.biofund@kurmapartners.com.

Feel free to reach out the team if you have any questions!

Join us in shaping the future of healthcare! Let's make a difference together 🚀.

Thierry Laugel Peter Neubeck Amanda Gett-Chaperot Rémi DrollerFlorence de Coorebyter Hadrien Bouchez

Kurma Portfolio News 🚀 : We are thrilled to announce that Stilla Technologies, a portfolio company of Kurma Partners, will be acquired by Bio-Rad Laboratories for up to $275 million, accelerating growth and innovation in the field of digital PCR instruments and assays.

🔎 Stilla Technologies, french company, provides digital PCR instruments and assays, offering innovative solutions capable of extracting precise genomic information from complex biological samples across a wide range of pharmaceutical, clinical, and research applications. The merger with Bio-Rad presents Stilla with the opportunity to accelerate its mission of delivering innovative dPCR solutions on a global scale.
Stilla’s flagship system, the Nio® System, recognized for its ease of use and multiplexing capabilities, has already been acknowledged for its transformative impact on life science research, clinical diagnostics, and biopharmaceutical applications.

💡 Following Bioserenity, Cardiologs and DNA Script, Stilla Technologies marks the fourth major exit of Kurma Diagnostics. Kurma Partners played a key role in Stilla’s growth and development by structuring the company’s Series A financing in 2018, raising €16 million. Kurma subsequently participated in Series B in 2020 (€20 million) and Series C in 2023 (€26.5 million).
As a venture capital firm specializing in life sciences, Kurma Partners has provided essential support and strategic guidance over the years, enabling Stilla to expand its capabilities and achieve significant milestones.

🗣 "We are proud to have been part of Stilla Technologies' remarkable journey. The resilience and visionary leadership of Rémi Dangla have been instrumental in guiding Stilla from its early days to becoming a leading player with its NioTM system". Philippe Peltier

Congratulations to Rémi Dangla and the whole Stilla team for their insight.
More information on : https://lnkd.in/eZzTd4i
Philippe Peltier Alain HORVAIS Kurma Partners Eurazeo

Portfolio news : Coave Therapeutics secures €32 million in Series A Financing to advance its next generation genetic Medicines.

💡 Coave Therapeutics is a genetic medicine company pioneering the development of innovative solutions to enhance the precision, safety, efficacy and manufacturability of genetic medicines. With its proprietary ALIGATERTM platform, Coave is at the forefront of addressing challenges in gene therapy delivery to extra-hepatic tissues, creating a robust pipeline targeting CNS, neuromuscular and eye diseases.

The financing will enable Coave to advance its proprietary ALIGATERTM (Advanced Vectors-Ligand Conjugates) platform, a breakthrough technology addressing key limitations in the delivery of genetic payloads to extra-hepatic tissues, including limited tissue specificity, delivery efficiency and safety.

Congratulations to Rodolphe Clerval and the whole team.

More information on : https://coavetx.com/

HR Opportunity : 🔎 We are looking for our futur intern for our growth Opportunities team !
You are a passionate and diligent individual with a scientific background, business sense and interest in supporting the development of breakthrough healthcare technologies (pharmaceuticals, devices, software) that will change the life of patients and caregivers.

🗓 When? March 2025
📍 Where? Paris or Munich
⏳ Duration? 6 months

📌 If you want to apply and join our team please send your resume along with a paragraph about yourself to candidature@kurmapartners.com.

Feel free to reach out the team if you have any questions!

Jean-Francois Rivassou Daniel Parera Maÿlis Deschamps

🤖 Raidium Raises €16 Million to Deploy the World’s First Foundation Model for Precision Radiology embedded in an AI-Native PACS Viewer 🚀

Very proud to announce Raidium's 16 million euro seed round, co-lead by Kurma Partners and Newfund, with additional support from Galion.exe, Founders Future, Debiopharm, the European Innovation Council (EIC) and Techmind. See link to Les Echos's coverage in the link below.

Ever since we led the pre-seed round in June 2023, we have been impressed by what Paul Herent, M.D., Msc, Pierre Manceron and their team have achieved. In a nutshell: groundbreaking ideas for the future of #AI in #radiology, combined with flawless execution!

I'm very excited about the next step for the company: time to make life easier for our Healthcare professionals and to create European champions in AI.

Thanks to everybody who contributed: Sebastian Schwarz, Laura Achach, Anne-Sophie Saint-Martin, Willy Braun, Louis Sautet, Vincent Lepreux Pascal Roux Yacine H. John Gridley Alain Decombe STATION F Roxanne VARZA MATWIN BioLabs SHARPSTONE Aurélie Boukerche Clémentine Gozard